Literature DB >> 1711014

Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen.

S R Attridge1, C Dearlove, L Beyer, L van den Bosch, A Howles, J Hackett, R Morona, J LaBrooy, D Rowley.   

Abstract

EX645 is a derivative of Salmonella typhi Ty21a which carries a plasmid specifying production of Vibrio cholerae O antigen. When cultured with exogenous galactose to overcome the galE defect of the vector, EX645 also synthesizes S. typhi O antigen, and this can result in the masking of the shorter V. cholerae O antigen on the bacterial surface. To determine whether the potential for such masking at least partly underlies the inconsistency of anti-V. cholerae responses elicited by EX645, a derivative of this strain has been isolated, characterized, and tested for immunogenicity in human volunteers. EX880 has an rfb defect which prevents synthesis of S. typhi O antigen, and consequently V. cholerae O antigen is still detectable on the surface of the clone following growth in the presence of galactose. Compared with EX645, EX880 more consistently elicited significant rises in serum bactericidal antibody levels, although individual responses within a cohort still varied widely.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711014      PMCID: PMC258007          DOI: 10.1128/iai.59.7.2279-2284.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  17 in total

1.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

2.  Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

Authors:  M M Levine; J B Kaper; D Herrington; G Losonsky; J G Morris; M L Clements; R E Black; B Tall; R Hall
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

3.  Identification of an intestinal immune response using peripheral blood lymphocytes.

Authors:  B D Forrest
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

4.  Characteristics of the attenuated oral vaccine strain "S. typhi" Ty 21a.

Authors:  R Germanier; E Fürer
Journal:  Dev Biol Stand       Date:  1983

5.  A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans.

Authors:  D M Hone; S R Attridge; B Forrest; R Morona; D Daniels; J T LaBrooy; R C Bartholomeusz; D J Shearman; J Hackett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

6.  Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.

Authors:  C O Tacket; B Forrest; R Morona; S R Attridge; J LaBrooy; B D Tall; M Reymann; D Rowley; M M Levine
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  Surface co-expression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210.

Authors:  S R Attridge; D Daniels; J K Morona; R Morona
Journal:  Microb Pathog       Date:  1990-03       Impact factor: 3.738

8.  Colonization of the mouse intestine by an avirulent Salmonella typhimurium strain and its lipopolysaccharide-defective mutants.

Authors:  J J Nevola; B A Stocker; D C Laux; P S Cohen
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

Review 9.  Progress in vaccines against typhoid fever.

Authors:  M M Levine; C Ferreccio; R E Black; C O Tacket; R Germanier
Journal:  Rev Infect Dis       Date:  1989 May-Jun

10.  IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine.

Authors:  A Tagliabue; L Villa; M T De Magistris; M Romano; S Silvestri; D Boraschi; L Nencioni
Journal:  J Immunol       Date:  1986-09-01       Impact factor: 5.422

View more
  5 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine.

Authors:  B D Forrest
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

Review 3.  Recombinant avirulent salmonellae as oral vaccine carriers.

Authors:  F Schödel
Journal:  Infection       Date:  1992 Jan-Feb       Impact factor: 3.553

Review 4.  Cholera.

Authors:  J B Kaper; J G Morris; M M Levine
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

5.  Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.

Authors:  D Favre; S J Cryz; J F Viret
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.